122 related articles for article (PubMed ID: 11009428)
1. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury.
Tracey WR; Magee WP; Ellery CA; MacAndrew JT; Smith AH; Knight DR; Oates PJ
Am J Physiol Heart Circ Physiol; 2000 Oct; 279(4):H1447-52. PubMed ID: 11009428
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury.
Ramasamy R; Oates PJ; Schaefer S
Diabetes; 1997 Feb; 46(2):292-300. PubMed ID: 9000707
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion.
Ramasamy R; Trueblood N; Schaefer S
Am J Physiol; 1998 Jul; 275(1):H195-203. PubMed ID: 9688914
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat.
Ramasamy R; Liu H; Oates PJ; Schaefer S
Cardiovasc Res; 1999 Apr; 42(1):130-9. PubMed ID: 10435004
[TBL] [Abstract][Full Text] [Related]
5. Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation.
Tracey WR; Magee W; Masamune H; Oleynek JJ; Hill RJ
Cardiovasc Res; 1998 Oct; 40(1):138-45. PubMed ID: 9876326
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
Beyer-Mears A; Diecke FP; Mistry K; Cruz E
Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase activation is a key component of myocardial response to ischemia.
Hwang YC; Sato S; Tsai JY; Yan S; Bakr S; Zhang H; Oates PJ; Ramasamy R
FASEB J; 2002 Feb; 16(2):243-5. PubMed ID: 11772943
[TBL] [Abstract][Full Text] [Related]
8. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Mylari BL; Larson ER; Beyer TA; Zembrowski WJ; Aldinger CE; Dee MF; Siegel TW; Singleton DH
J Med Chem; 1991 Jan; 34(1):108-22. PubMed ID: 1899452
[TBL] [Abstract][Full Text] [Related]
9. Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart.
Tracey WR; Magee W; Masamune H; Kennedy SP; Knight DR; Buchholz RA; Hill RJ
Cardiovasc Res; 1997 Feb; 33(2):410-5. PubMed ID: 9074706
[TBL] [Abstract][Full Text] [Related]
10. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
11. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.
Auchampach JA; Ge ZD; Wan TC; Moore J; Gross GJ
Am J Physiol Heart Circ Physiol; 2003 Aug; 285(2):H607-13. PubMed ID: 12689858
[TBL] [Abstract][Full Text] [Related]
12. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
Ge ZD; Peart JN; Kreckler LM; Wan TC; Jacobson MA; Gross GJ; Auchampach JA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1200-10. PubMed ID: 16985166
[TBL] [Abstract][Full Text] [Related]
13. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts.
Trueblood N; Ramasamy R
Am J Physiol; 1998 Jul; 275(1):H75-83. PubMed ID: 9688898
[TBL] [Abstract][Full Text] [Related]
14. Central role for aldose reductase pathway in myocardial ischemic injury.
Hwang YC; Kaneko M; Bakr S; Liao H; Lu Y; Lewis ER; Yan S; Ii S; Itakura M; Rui L; Skopicki H; Homma S; Schmidt AM; Oates PJ; Szabolcs M; Ramasamy R
FASEB J; 2004 Aug; 18(11):1192-9. PubMed ID: 15284219
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX.
Kilpatrick EL; Narayan P; Mentzer RM; Lasley RD
Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H847-53. PubMed ID: 11454590
[TBL] [Abstract][Full Text] [Related]
16. Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor.
Kuruvilla R; Eichberg J
J Neurochem; 1998 Aug; 71(2):775-83. PubMed ID: 9681469
[TBL] [Abstract][Full Text] [Related]
17. The effect of body temperature on myocardial protection conferred by ischaemic preconditioning or the selective adenosine A1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion.
Sheldrick A; Gray KM; Drew GM; Louttit JB
Br J Pharmacol; 1999 Sep; 128(2):385-95. PubMed ID: 10510449
[TBL] [Abstract][Full Text] [Related]
18. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
Beyer-Mears A; Mistry K; Diecke FP; Cruz E
Pharmacology; 1996 May; 52(5):292-302. PubMed ID: 8807673
[TBL] [Abstract][Full Text] [Related]
19. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.
Tracey WR; Magee WP; Oleynek JJ; Hill RJ; Smith AH; Flynn DM; Knight DR
Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2780-7. PubMed ID: 12919933
[TBL] [Abstract][Full Text] [Related]
20. Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.
Mylari BL; Beyer TA; Scott PJ; Aldinger CE; Dee MF; Siegel TW; Zembrowski WJ
J Med Chem; 1992 Feb; 35(3):457-65. PubMed ID: 1738141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
